Predictive Biosciences Launches Prostate Cancer Test Based on Epigenomics AG's DNA Methylation Marker

Published: Jan 29, 2013

Berlin, Germany, Seattle, WA, and Lexington, MA, U.S.A., January 29, 2013 - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, and Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced that Predictive Biosciences of Lexington, MA, has made commercially available a novel tissue-based test for prostate cancer biopsy confirmation utilizing Epigenomics’ proprietary DNA methylation marker GSTP1.

Pierre Cassigneul, Chief Executive Officer of Predictive Biosciences, stated: “We are excited to build upon our existing CertNDx™ commercial franchise in bladder cancer, with the first of several novel tests we plan to commercialize over the next few years which will address the significant unmet diagnostic clinical needs in prostate cancer”. Additionally, Noel Doheny, Chief Executive Officer of Epigenomics’ US subsidiary, commented: “We are pleased that Predictive Biosciences has successfully moved forward to introduce their assay based on Epigenomics’ intellectual property into the market. This further demonstrates the growing importance of DNA methylation based tests in cancer diagnostics”.

Contact Epigenomics AG

Antje Zeise

Manager IR | PR

Epigenomics AG

Tel +49 (0) 30 24345 368

About Predictive Biosciences

Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. For additional information, please visit

About Epigenomics

Epigenomics ( is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.

Back to news